Intellia Therapeutics, Inc. · Transaction Feb 28, 2022 · Filed Mar 3, 2022 · $15,001 to $50,000
XNAS · NTLA
-1.16% · -$0.1400 · Vol Not reported
Pre-market · updated 04:07:02 ET
Intellia Therapeutics, Inc
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
$11.95
Veridion Score
BETAHIGH CONF · 6/6 factorsMon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET · NTLA
MethodologyNTLA
Intellia Therapeutics, Inc
Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
SELL BIAS
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
42/ 100
Veridion Score
SELL BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is NTLA moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Intellia Therapeutics, Inc
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESListed since
2016
Employees
377
Country
US
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$12.09
Last session
Day high
$12.09
Last session
Day low
$12.09
Last session
Previous close
$12.09
52W high
$27.98
-57.29% from high
52W low
$8.04
20% of range
Market cap
$1.7B
Beta
2.19
Shares out
140.1M
Avg volume
3.9M
VWAP
$12.09
Last session
Price history computed in-house
1W
-0.58%
1M
+5.05%
3M
-2.53%
1Y
+11.37%
YTD
+32.93%
SMA 50 $13.33 · below
SMA 200 $12.43 · below
52W position 20%
NTLA overview
Related filings and maps
Public disclosures
Congress activity in NTLA
Official filing ↗
Intellia Therapeutics, Inc. · Transaction Oct 29, 2021 · Filed Oct 30, 2021 · $1,001 to $15,000
Intellia Therapeutics, Inc. · Transaction Sep 20, 2021 · Filed Oct 1, 2021 · $1,001 to $15,000
Intellia Therapeutics, Inc. · Transaction Jul 21, 2021 · Filed Aug 7, 2021 · $1,001 to $15,000
Intellia Therapeutics, Inc. · Transaction Jan 15, 2021 · Filed Jan 31, 2021 · $1,001 to $15,000
Federal contracts
NTLA contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NTLA in this window.
Lobbying spend
NTLA lobbying filings, year to date.
Registered lobbying filings matched to Intellia Therapeutics, Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NTLA in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for NTLA.
Options
Sovereign unlock shows live options positioning for NTLA.